Patient characteristics | Intervention group | Control group | P value | ||
N=255 | N=83 | ||||
Age (median in years, IQR) | 31 | (21–44) | 32 | (20–50) | 0.6161* |
Sex | |||||
Male | 144 | 56% | 50 | 60% | 0.546† |
Female | 111 | 44% | 33 | 40% | |
Chest X-ray | |||||
Test assigned | 173 | 68% | 27 | 33% | <0.001† |
Underwent CXR | 168 | 66% | 24 | 29% | <0.001† |
Smear | |||||
Test assigned | 134 | 53% | 30 | 36% | 0.009† |
Underwent smear | 111 | 44% | 26 | 31% | 0.049† |
GeneXpert | |||||
Test assigned | 166 | 65% | 41 | 49% | 0.011† |
Underwent GeneXpert | 142 | 56% | 27 | 33% | <0.001† |
TB case type | |||||
Microbiologically confirmed cases | 61 | 24% | 9 | 11% | <0.001† |
Clinically diagnosed, Micro negative | 82 | 32% | 18 | 22% | |
Clinically diagnosed, Micro unknown | 112 | 44% | 56 | 67% | |
Duration from symptom onset to pharmacy provider referral (median in days, IQR) | 30 | (20–60) | NA | NA | |
Duration from pharmacy provider referral to TB treatment initiation (median in days, IQR) | 5 | (2–11) | 1 | (0–8) | <0.001* |
*Wilcoxon rank-sum test.
†χ2 test.
CXR, chest radiograph; NA, Not available; TB, tuberculosis.